Literature DB >> 12476389

[Osteosarcoma and Ewing's sarcoma--The most frequent malignant bone tumors in children--therapy and outcome].

M Sluga1, R Windhager, M Pfeiffer, P Ofner, S Lang, M Dominkus, S Nehrer, A Zoubek, R Kotz.   

Abstract

BACKGROUND: Osteosarcoma and Ewing's sarcoma are the most frequent malignant bone tumors in children and young adults with relatively poor overall survival rates.
METHODS: Between January 1980 and December 1994, 175 children with osteosarcoma and 64 children with Ewing's sarcoma were treated at the author's institution. 22 children had synchronous metastases, 19 patients had a pathologic fracture. Both groups were treated systemically with chemotherapy regimens (COSS and CESS). Local therapy was amputation or tumor resection and endoprosthetic replacement or biological reconstruction with wide or radical resection margins. In case of Ewing's sarcoma in 35 patients postoperative radiation therapy was done.
RESULTS: Five-year overall survival rate for osteosarcoma and Ewing's sarcoma patients is about 63 %, ten-year survival rate for osteosarcoma patients is 60.2 %, for Ewing's sarcoma patients 54.5 %. Prognostic factors significantly influencing overall survival rates are tumor response to chemotherapy (p values = 0.0056 and 0.013, respectively), surgical treatment with adequate resection margins (p value = 0.0001 for osteosarcoma patients) and development of postoperative metastases (p value = 0.0001 for both groups).
CONCLUSION: For both groups of malignant bone tumors systemic chemotherapy as well as adequate surgical therapy are necessary to reduce the rates of local recurrences and to achieve better survival rates.

Entities:  

Mesh:

Year:  2002        PMID: 12476389     DOI: 10.1055/s-2002-36040

Source DB:  PubMed          Journal:  Z Orthop Ihre Grenzgeb        ISSN: 0044-3220


  9 in total

1.  Dioscin inhibits stem-cell-like properties and tumor growth of osteosarcoma through Akt/GSK3/β-catenin signaling pathway.

Authors:  Weihai Liu; Zhiqiang Zhao; Yongqian Wang; Wuguo Li; Qiao Su; Qiang Jia; Jiajun Zhang; Xuelin Zhang; Jingnan Shen; Junqiang Yin
Journal:  Cell Death Dis       Date:  2018-03-01       Impact factor: 8.469

2.  An Innovative Therapeutic Option for the Treatment of Skeletal Sarcomas: Elimination of Osteo- and Ewing's Sarcoma Cells Using Physical Gas Plasma.

Authors:  Josephine M Jacoby; Silas Strakeljahn; Andreas Nitsch; Sander Bekeschus; Peter Hinz; Alexander Mustea; Axel Ekkernkamp; Mladen V Tzvetkov; Lyubomir Haralambiev; Matthias B Stope
Journal:  Int J Mol Sci       Date:  2020-06-23       Impact factor: 5.923

3.  Concurrent Osteosarcoma Theranostic Strategy Using Contrast-Enhanced Ultrasound and Drug-Loaded Bubbles.

Authors:  Tai-Tzung Kuo; Chung-Hsin Wang; Jir-You Wang; Hong-Jen Chiou; Ching-Hsiang Fan; Chih-Kuang Yeh
Journal:  Pharmaceutics       Date:  2019-05-08       Impact factor: 6.321

4.  Short Hairpin RNA (shRNA) Ether à go-go 1 (Eag1) inhibition of human osteosarcoma angiogenesis via VEGF/PI3K/AKT signaling.

Authors:  Jin Wu; Xinyu Wu; Daixing Zhong; Wenliang Zhai; Zhenqi Ding; Yong Zhou
Journal:  Int J Mol Sci       Date:  2012-10-01       Impact factor: 5.923

5.  Voltage-gated potassium channel Kv1.3 is highly expressed in human osteosarcoma and promotes osteosarcoma growth.

Authors:  Jin Wu; Daixing Zhong; Xinyu Wu; Mo Sha; Liangqi Kang; Zhenqi Ding
Journal:  Int J Mol Sci       Date:  2013-09-23       Impact factor: 5.923

6.  Silencing of Ether à go-go 1 by shRNA inhibits osteosarcoma growth and cell cycle progression.

Authors:  Jin Wu; Daixing Zhong; Xijin Fu; Qingjun Liu; Liangqi Kang; Zhenqi Ding
Journal:  Int J Mol Sci       Date:  2014-04-01       Impact factor: 5.923

7.  Down-regulation of tumor endothelial marker 8 suppresses cell proliferation mediated by ERK1/2 activity.

Authors:  Chuangjie Cao; Zhuo Wang; Leilei Huang; Lihong Bai; Yuefeng Wang; Yingjie Liang; Chengyun Dou; Liantang Wang
Journal:  Sci Rep       Date:  2016-03-21       Impact factor: 4.379

8.  Silencing of hERG1 Gene Inhibits Proliferation and Invasion, and Induces Apoptosis in Human Osteosarcoma Cells by Targeting the NF-κB Pathway.

Authors:  Wenrong Zeng; Qingjun Liu; Zhida Chen; Xinyu Wu; Yuanfu Zhong; Jin Wu
Journal:  J Cancer       Date:  2016-04-10       Impact factor: 4.207

9.  A Atractylodes lancea polysaccharide inhibits metastasis of human osteosarcoma U-2 OS cells by blocking sialyl Lewis X (sLex )/E-selectin binding.

Authors:  Kaihua Zhong; Shuxin Fan; Shujun Yao; Haibin Xu; Suping Bai
Journal:  J Cell Mol Med       Date:  2020-09-28       Impact factor: 5.310

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.